News >

Flinn Highlights Emerging Combinations in CLL

Danielle Bucco
Published: Monday, Feb 26, 2018

Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD
Several promising combinations are being investigated for patients with chronic lymphocytic leukemia (CLL), according to Ian W. Flinn, MD, citing a number of ongoing trials presented at the 2017 ASH Annual Meeting.

on Hematologic Malignancies, Flinn, director of the Blood Cancer Research Program at Sarah Cannon Research Institute, discussed ongoing advances with emerging combination regimens in CLL.

OncLive®: What recent advances have we seen in CLL?

Flinn: There are changes in the way we are treating patients with CLL. We now have the wonderful advancement of BTK inhibitors, such as ibrutinib (Imbruvica). Patients will stay on these therapies indefinitely, which has changed the natural history of the disease. We are moving the field along and are developing combination regimens.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication